EROAD (ERD)•HY26•Released 21 November 2025EBITDA flat but NZD 136.6m impairment collapse drove NPAT to -NZD 144.2mRevenue grew 3.3% and cash generation improved sharply, but a large goodwill/asset impairment obliterated reported earnings and equity.Published 21 April 2026Read briefing→
EROAD (ERD)•FY25•Released 26 May 2025EROAD's FCF jumped to $16.0m on a capex halving, not on stronger operating cashEBITDA rose 11.8% but operating cash fell 18.3%, and whether the FCF step-up is durable hinges on post–4G-upgrade investment intensity.Published 22 April 2026Read briefing→
EROAD (ERD)•FY24•Released 23 May 2024FCF swings +$31.2m and net debt halves, but PBT loss widened 37%Operating cash generation more than doubled and leverage collapsed to 0.4x EBITDA, yet pre-tax losses deepened and only a tax benefit held NPAT...Published 22 April 2026Read briefing→
EROAD (ERD)•HY24•Released 29 November 2023EBITDA up 23% but pre-tax loss widens to $4.3m as D&A and interest biteCash generation and leverage improved sharply, but receivable days blew out by 12 days and reported NPAT slipped back into loss.Published 22 April 2026Read briefing→
EROAD (ERD)•FY23•Released 24 May 2023EROAD FY23: revenue up 52% on Coretex, but net debt triples to $62.5mReported losses narrowed and guidance was met, but cash conversion slipped, receivable days doubled, and leverage moved to 1.4x EBITDA.Published 21 April 2026Read briefing→